Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Evaluate AVA004 in Patients with Advanced PD-L1 Positive Solid Tumours

Trial Profile

A Phase I Study to Evaluate AVA004 in Patients with Advanced PD-L1 Positive Solid Tumours

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVA-004 (Primary) ; AVA-004 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
  • Sponsors Avacta
  • Most Recent Events

    • 10 Jun 2019 According to an Avacta media release, the company has selected the clinical development candidate AVA004, for first-time-in-human clinical trial of the Affimer platform.The company remains on track to submit an IND/CTA application for AVA004 by the end of 2020 and dosing of first patients shortly afterwards.
    • 09 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top